Jump to content

New pages

New pages
Hide bots | Hide redirects | Hide reviewed edits
(newest | oldest) View ( | ) (20 | 50 | 100 | 250 | 500)

23 May 2026

22 May 2026

20 May 2026

19 May 2026

  • 06:2206:22, 19 May 2026 THCV (hist | edit) [1,405 bytes] MDElliottMD (talk | contribs) (Create Tetrahydrocannabivarin (THCV) medicine stub: minor phytocannabinoid, propyl analogue of THC, biphasic CB1 activity (low-dose neutral antagonist, high-dose partial agonist), investigational interest in appetite suppression and type 2 diabetes. Cites Russo 2011 (PMID 21749363).)
  • 06:2206:22, 19 May 2026 CBG (hist | edit) [1,502 bytes] MDElliottMD (talk | contribs) (Create Cannabigerol (CBG) medicine stub: minor phytocannabinoid, biosynthetic precursor from CBGA to THCA/CBDA/CBCA, non-psychoactive, multiple non-CB pharmacology targets. Cites Russo 2011 (PMID 21749363).)
  • 06:2206:22, 19 May 2026 CBN (hist | edit) [1,144 bytes] MDElliottMD (talk | contribs) (Create Cannabinol (CBN) medicine stub: minor phytocannabinoid, THC oxidation product, weak CB1 partial agonist, popularly framed as a sleep cannabinoid with sparse controlled evidence. Cites Russo 2011 entourage-effect review (PMID 21749363).)
  • 06:2206:22, 19 May 2026 CBD (hist | edit) [74 bytes] MDElliottMD (talk | contribs) (Create CBD as redirect to Cannabidiol; tagged into Category:Medicines + Category:Cannabinoids per the alternate-name pattern (cf. Heroin -> Diacetylmorphine). Closes the CBD redlink that the Cannabis exemplar page surfaced.) Tag: New redirect
  • 03:1603:16, 19 May 2026 Lixisenatide (hist | edit) [807 bytes] MDElliottMD (talk | contribs) (Create Lixisenatide stub: short-acting GLP-1 receptor agonist (Adlyxin / Lyxumia, FDA 2016, withdrawn from US market 2023). Closes last redlink in Category:GLP-1 receptor agonists.)

18 May 2026

(newest | oldest) View ( | ) (20 | 50 | 100 | 250 | 500)